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Objectives. This study investigates the suitability, safety, and efficacy of vernakalant in critically ill patients with new onset atrial
fibrillation (AF) after cardiac surgery. Methods. Patients were screened for inclusion and exclusion criteria according to the
manufacturers’ recommendations. Included patients were treated with 3mg/kg of vernakalant over 10min and, if unsuccessful, a
second dose of 2mg/kg. Blood pressure wasmeasured continuously for 2 hours after treatment.Results. Of the 191 patients screened,
159 (83%) were excluded, most importantly due to hemodynamic instability (59%). Vernakalant was administered to 32 (17% of the
screened) patients. Within 6 hours, 17 (53%) patients converted to sinus rhythm. Blood pressure did not decrease significantly 10,
30, 60, and 120minutes after the vernakalant infusion. However, 11 patients (34%) experienced a transient decrease in mean arterial
blood pressure <60mmHg. Other adverse events included nausea (𝑛 = 1) and bradycardia (𝑛 = 2). Conclusions. Applying the strict
inclusion and exclusion criteria provided by the manufacturer, only a minority of postoperative ICU patients with new onset AF
qualified for vernakalant. Half of the treated patients converted to sinus rhythm. The drug was well tolerated, but close heart rate
and blood pressure monitoring remains recommended.
1. Background
Atrial fibrillation (AF) remains a clinical challenge for physi-
cians caring for critically ill patients [1]. It is frequent in
patients hospitalized in the intensive care unit (ICU) and par-
ticularly common in patients after cardiac surgery [2, 3]. Up
to a third of patients undergoing coronary artery bypass
grafting (CABG) and/or valve surgery develop postoperative
AF [4, 5]. It is often poorly tolerated, particularly in the first
days postoperatively or in cases of diastolic dysfunction.
Intravenous amiodarone is commonly used in the ICU
setting, even though the conversion rate into sinus rhythm
is moderate [6, 7]. A wide range of cardiac (e.g., negative ino-
tropic, QT prolongation) and noncardiac adverse effects (e.g.,
thyroid disorders, liver and lung toxicity, neuropathy, and
photosensitivity) as well as a very long half-life can cause
problems in treated patients. Other antiarrhythmic drugs
such as propafenone, flecainide, or ibutilide can rarely be used
in ICU patients with AF, because they are contraindicated
in patients with structural heart disease due to a high risk
of proarrhythmic side effects [8, 9]. Hence, rapidly acting,
efficacious, and well-tolerated drugs for the treatment of AF
are urgently needed.
Vernakalant is a novel antiarrhythmic agent with an
atrial-specific mechanism of action [10]. It is a multichannel
blocker which inhibits the potassium currents 𝐼kur and
𝐼KACh, resulting in a prolongation of the action potential
repolarization. Additionally, vernakalant exerts an inhibitory
action on sodium channels [11].The atrium-specific effect was
demonstrated in an electrophysiology study in 19 patients,
in which the intravenous application of vernakalant signifi-
cantly prolonged the atrial, but not the ventricular, refractory
period [12]. The drug is metabolized by cytochrome P2D6.
The elimination half-life in fast and slow metabolizers is 3
and 5.5 hours, respectively. No dose adjustments are needed
in patients with advanced age, renal and liver dysfunction.
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Case reports indicate that vernakalant might be an inter-
esting treatment option in critically ill patients [13]. However,
systematic reports on the usefulness of this substance in
this particular population are lacking. Therefore, the current
study was designed to answer the following questions.
(1) Howmany ICU patients with new onset AF after car-
diac surgery qualify for vernakalant according to
inclusion and exclusion criteria provided by the offi-
cial drug information (suitability)?
(2) What is the conversion rate to sinus rhythm after
administration of vernakalant in critically ill patients
(efficacy)?
(3) What hemodynamic and adverse effects of vernaka-
lant occur in responders and nonresponders (safety)?
2. Methods
2.1. Patients. The study was performed in the Cardiosurgical
ICU at the University Hospital Zurich, Switzerland. In the
year 2012, 1,044 patients were admitted to this 12-bed unit,
the majority of them after cardiac or major vascular surgery.
Median SAPS and ICU length of stay of all admitted patients
were 27 and 3.5 days, respectively. Patients were included
into this study if they were ≥18 years old and suffered from
new onset (<7 days) AF. Electrocardiogram (ECG), blood
pressure, and oxygen saturation were monitored continu-
ously in all patients. Patients did not qualify for vernakalant
and were therefore excluded from the survey, if they ful-
filled one or more of the following criteria: cardiovascular
instability (noradrenaline dose ≥0.1mcg/kg/min); need for
inotropes; atrial flutter; myocardial infarction (ST elevation
or non-ST elevation) within 30 days; QT(not corrected) inter-
val >440ms; intravenous administration of antiarrhythmic
drugs of classes I or III (amiodarone) 4 hours prior to
the planned vernakalant infusion; liver cirrhosis Child C;
pregnancy, lactation; allergy against vernakalant. In order
to reduce the risk of thromboembolic complications, ver-
nakalant was only administered, if (a) AF persisted for less
than 48hour, (b) a surgical left atrial appendage occlusionhad
been performed during cardiac surgery, or (c) a thrombus
in the atrium or left atrial appendage was excluded by
transesophageal echocardiography. Potassium serum levels
were kept between 4.5 and 5.5mmol/L. Magnesium was
substituted prior to the study drug infusion if the serum level
was <1.0mmol/L.
2.2. Vernakalant. Vernakalant (Brinavess) was adminis-
tered via infusion according to the manufacturer’s recom-
mendations at a dose of 3mg/kg over 10minutes. If no conver-
sion occurred 15 minutes after the end of the first infusion, a
second dose of 2mg/kg was administered as an infusion over
10 minutes. In patients weighing ≥100 kg, first and second
doses of 300mg and 200mg were used (500mg maximum).
Responders were defined as patients who converted to
sinus rhythm within 6 hours after the vernakalant adminis-
tration.
2.3. Monitoring. Patient characteristics and laboratory values
were recorded from the patients’ charts. No extra blood was
taken or analyzed for this study. Heart rhythm and rate as well
as blood pressure were monitored continuously for at least 2
hours after the vernakalant infusion and recorded 10, 30, 60,
and 120 minutes after the first infusion. Adverse events were
recorded at any time point, but symptoms such as nausea or
dysgeusia were not particularly asked for.
2.4. Statistics. All datawere collected from the patient’s charts
and entered into a database. Median (range) or percentages
were calculated for the overall sample and subgroups. Com-
parisons between groups were made with the use of the
Mann-Whitney𝑈 test or the Fisher exact test, as appropriate.
Repeated measures within groups were compared with a
Wilcoxon signed rank sum test. The null hypothesis was
rejected with a two-sided 𝑃 value of <0.05. All analyses were
performed with the use of SPSS for Mac OS X.
2.5. Ethical Considerations. Vernakalant has been licensed
in Switzerland and the drug was used according to the
manufacturer’s recommendation. As the study was designed
as a survey (field report), no informed consent was required
for this type of study.The study protocol was approved by the
Clinical Trial Center at the University Zurich and the local
ethical committee (KEK-ZH-Nr. 2011-0396).
3. Results
3.1. Suitability. A total of 191 patients with AF were screened
(132 men, 59 women). Of these patients, 159 (83%) were
excluded due to hemodynamic instability (𝑛 = 113; 59%),
self-limiting AF (𝑛 = 19; 9.9%), chronic AF (𝑛 = 13;
6.8%), prior intravenous amiodarone treatment (𝑛 = 11;
5.8%), myocardial infarction (𝑛 = 7; 3.7%), and/or long
QT interval (𝑛 = 5; 2.6%). Vernakalant was adminis-
tered to 32 (17% of the screened) patients. In these patients,
AF occurred on average on the 4th (1st–16th) postopera-
tive day. Baseline characteristics and laboratory parameters
prior to vernakalant treatment are given in Tables 1 and 2.
Five patients (16%) had a left-ventricular ejection fraction
≤45%.
3.2. Efficacy. Six patients (21%) converted directly after the
first dose of vernakalant, but 26 (79%) patients did not and
required a second dose. Within 6 hours, 17 (53%) patients
converted to sinus rhythm (responders) and 15 (47%) did
not (nonresponders). The time to conversion was 30 (4–
355) minutes in responders. AF was normocard in 5 (33%)
nonresponders and in 2 (12%) responders (𝑃 = 0.21).
Responders had slightly but significantly lower magnesium
levels at baseline than nonresponders (Table 2). Intravenous
magnesium sulfate (22mval) was administered to 5 (33%)
nonresponders and 9 (53%) responders (𝑃 = 0.31) prior to
the vernakalant infusion. Of the responders, 5 (29%) had a
relapse ofAFduring the 6-hour observation period.Outcome
parameters are given in Table 4.
Critical Care Research and Practice 3
Table 1: Baseline characteristics.
Parameters All (𝑛 = 32) Responders (𝑛 = 17) Nonresponders (𝑛 = 15) 𝑃 value
Age—years 74 (36–86) 74 (49–86) 76 (36–83) 0.77
Male gender 22 (69%) 10 (59%) 12 (80%) 0.27
Weight—kg 83 (58–108) 83 (62–100) 82 (58–108) 0.77
Height—cm 173 (145–184) 173 (150–180) 172 (145–184) 0.83
Type of surgery
Coronary artery bypass 13 (41%) 7 (41%) 6 (40%) 1.00
Valve 18 (56%) 10 (59%) 8 (53%) 1.00
Major vascular 9 (28%) 4 (24%) 5 (33%) 0.70
SAPS 37 (18–64) 35 (18–64) 39 (21–63) 0.79
LV ejection fraction—% 57 (35–80) 60 (45–62) 55 (35–80) 0.59
Mechanical ventilation 14 (44%) 7 (41%) 7 (47%) 0.47
Dialysis 7 (22%) 3 (18%) 4 (27%) 0.86
LV: left-ventricular; SAPS: simplified acute physiology score. Results are given as median (minimum–maximum) or numbers (percentages). Groups were
compared with Fisher’s exact test or the Mann-Whitney𝑈 test, as appropriate.
Table 2: Laboratory values prior to treatment.
Parameters All (𝑛 = 32) Responders (𝑛 = 17) Nonresponders (𝑛 = 15) 𝑃 value
Hematocrit—% 27 (20–38) 27 (20–38) 27 (24–38) 0.77
WBC (×109/L) 12 (2.0–35) 12 (2.0–16) 12 (6.2–35) 0.60
Potassium—mmol/L 4.9 (4.0–5.2) 4.7 (4.3–5.2) 4.9 (4.0–5.1) 0.55
Magnesium—mmol/L 0.94 (0.77–2.3) 0.91 (0.77–1.6) 1.03 (0.88–2.3) 0.03
C-reactive protein—mg/L 123 (2–312) 122 (2–312) 124 (30–309) 0.79
Procalcitonin—ng/L 1.1 (0.30–29) 1.4 (0.50–29) 0.97 (0.30–17) 0.63
Creatine kinase—U/L 269 (11–762) 279 (11–762) 204 (39–567) 0.88
Troponin—ug/L 0.40 (0.04–4.8) 0.37 (0.04–4.8) 0.41 (0.07–1.5) 0.75
Creatinine—umol/L 92 (48–535) 92 (48–535) 92 (55–534) 0.88
Urea—mmol/L 11 (3.4–25) 8.8 (4.8–16) 11 (3.4–25) 0.18
Base excess −0.55 (−6.6–+6.3 −0.55 (−2.7–+6.3) −0.35 (−6.6–+1.5) 0.42
Bicarbonate—mmol/L 24 (20–30) 24 (22–30) 25 (20–26) 0.56
WBC: white blood cell count. Results are given as median (minimum–maximum). Groups were compared with the Mann-Whitney𝑈 test.
3.3. Safety. Hemodynamic changes are illustrated in Figure 1
and Table 3. A drop in heart rate <60/min was documented
in 2 patients (6.3%), of which 1 episode led to a transient
drop in SvO2 (Figure 2). A decrease in mean arterial BP
<60mmHg occurred in 3 (27%) of the nonresponders and
8 (47%) of the responders (𝑃 = 0.15). Four patients (12.5%;
2 responders and 2 nonresponders) required therefore either
noradrenaline boli or an increase of the noradrenaline infu-
sion rate >0.1mcg/kg/min. One patient reported nausea, but
no patient complained about dysgeusia. No patient developed
ventricular tachycardia or torsades de pointes.
4. Discussion
In this postmarketing survey, we assessed the suitability,
efficacy, and safety of vernakalant in ICU patients with new
onset AF after cardiac surgery. To our knowledge, this is the
first report focusing on the effects of vernakalant in criti-
cally ill patients with a high prevalence of structural heart
disease.
4.1. Suitability. Strictly applying inclusion and exclusion
criteria recommended by the manufacturer, the majority of
screened patients could not be treated with vernakalant.
The most important exclusion criterion was hemodynamic
instability, which was defined as a noradrenaline requirement
≥0.1mcg/kg/min, the need of inotropes, or the use of a
mechanical cardiac assist device. Other relevant exclusion
criteria were previous or ongoing treatment with intravenous
amiodarone, a history of recent myocardial infarction, and
QT prolongation >440ms (not corrected). At the end, 32
critically ill patients with new onset AF were treated with
vernakalant, which is to date the largest series of vernakalant-
treated ICU patients. The high severity of illness in this
population is reflected by the facts that median SAPS was 37,
44% were on mechanical ventilation, 34% required low-dose
vasopressors, and 22% of the patients depended on dialysis.
Of note, the majority of patients suffered from systemic
inflammation with median values of white blood cell count
and C-reactive protein level of 12 × 109/L and 123mg/L,
respectively.
4.2. Efficacy. When vernakalant was administered at a first
dose of 3mg/kg over 10 minutes with a second dose of
2mg/kg if necessary, more than half of the patients converted
from AF to sinus rhythm. This conversion rate is similar
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Figure 1: The lines show individual changes of mean arterial pressure (MAP) and heart rate (HR) of nonresponders and responders during
the 2 h observation period.
(a) (b)
Figure 2: (a)The ECG of this 61-year-old patient 3 days after aortocoronary bypass grafting shows atrial fibrillation (HR 129–136/min) and a
left bundle branch block. (b) After 2 doses of vernakalant, the patient converted into sinus rhythm (HR 57/min). Bradycardia decreased SvO2
to 49% and required temporary atrial pacing via the existing epicardial leads.
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Table 3: Hemodynamic changes during treatment.
Parameters All (𝑛 = 32) Responders (𝑛 = 17) Nonresponders (𝑛 = 15) 𝑃 value
Maximum HR—1/min
At baseline 127 (70–163) 128 (75–160) 115 (70–163) 0.39
After 10 minutes 112 (60–146) 111 (70–140) 113 (60–146) 0.55
After 30 minutes 105 (61–155) 92 (64–146) 110 (61–155) 0.43
After 60 minutes 99 (69–139) 89 (70–130) 110 (69–139) 0.47
After 120 minutes 95 (70–158) 89 (70–146) 107 (74–158) 0.26
NA requirements
At baseline 11 (34%) 6 (35%) 5 (33%) 1.00
Dose—mcg/kg/min 0.00 (0.00–0.10) 0.00 (0.00–0.05) 0.00 (0.00–0.10) 0.82
MAP
At baseline 67 (54–90) 65 (54–86) 68 (62–90) 0.11
After 10 minutes 73 (57–103) 72 (57–92) 75 (62–103) 0.58
After 30 minutes 77 (55–103) 72 (55–88) 84 (59–103) 0.02
After 60 minutes 70 (54–101) 70 (54–101) 75 (55–96) 0.19
After 120 minutes 72 (60–106) 71 (60–85) 76 (62–106) 0.04
Lactate—mmol/L
At baseline 1.1 (0.6–2.1) 1.0 (0.6–2.1) 1.1 (0.8–1.6) 0.92
After 120 minutes 1.2 (0.6–3.1) 1.1 (0.6–3.1) 1.3 (0.9–1.5) 0.79
SvO2 —%
At baseline 63 (49–75) 64 (51–75) 60 (49–75) 0.22
After 120 minutes 65 (48–75) 63 (48–75) 65 (55–72) 0.75
HR: heart rate; MAP: mean arterial pressure; NA: noradrenaline. Results are given as median (minimum–maximum) or numbers (percentages). Groups were
compared with Fisher’s exact test or the Mann-Whitney𝑈 test, as appropriate.
Table 4: Outcome.
Parameters All (𝑛 = 32) Responders (𝑛 = 17) Nonresponders (𝑛 = 15) 𝑃 value
ICU length of stay—days 6 (1–62) 6 (1–23) 6 (2–62) 0.26
Sinus rhythm on ICU—discharge 23 (74%) 14 (88%) 9 (60%) 0.11
Survival 32 (100%) 17 (100%) 15 (100%) 1.00
Results are given as median (minimum–maximum) or numbers (percentages). Groups were compared with Fisher’s exact test or the Mann-Whitney𝑈 test, as
appropriate.
to published results from previous trials performed in non-
ICU patients. The CRAFT trial (conversion of rapid atrial
fibrillation trial), a phase II multicenter clinical trial, ran-
domized 56 patients to placebo (𝑛 = 20) and two different
dosages of vernakalant (𝑛 = 18 for each group) [14]. High-
dose treatment with vernakalant (2mg/kg over 10 minutes
followed by 3mg/kg if AF was still present after the first
dose) converted AF to sinus rhythm in 61% of treated patients
versus 5% of patients in the control group. The ACT (atrial
arrhythmia conversion) trials I–IV [15–18] were phase III
studies demonstrating efficacy and safety of vernakalant in
hemodynamic stable patients with new onset AF. The drug
was generally well tolerated with a conversion rate consis-
tently around 50%. Kowey et al. compared vernakalant and
placebo in noncritically ill patients with AF after cardiac
surgery, and the conversion rates within 90minutes of dosing
were 47% and 14%, respectively [17].The AVRO study (phase
III superiority study of vernakalant versus amiodarone in
subjects with recent onset atrial fibrillation) demonstrated
that vernakalant was more effective than amiodarone for the
rapid conversion of AF to sinus rhythm (51.7% versus 5.7%
at 90 minutes after start of treatment) [19]. Recently, Torp-
Pedersen and coworkers demonstrated that the conversion
rate of vernakalant was independent of a history of ischemic
heart disease [20].
However, some of our patients had a relapse to AF,
leading to a final conversion rate of 33% beyond 6 hours.
Interestingly, this conversion rate is still better than that
after electrical conversion in critically ill patients. Mayr et al.
described success rates immediately, 24 hours, and 48 hours
after electrical conversion of 35%, 24%, and 16%, respectively
[21]. Hence, the conversion rates of electrical cardioversion
are much lower in critically ill patients compared to non-ICU
patients [22].
The recurrence of AF after initially successful pharmaco-
logical or electrical conversion might be reduced by concur-
rent use of other drugs, for example, beta-blockers, but this
must be investigated in future studies.
4.3. Safety. Vernakalant was well tolerated in our population
of critically ill patients with a high prevalence of structural
heart disease. Overall, the blood pressure values did not drop
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significantly 10, 30, 60, and 120 minutes after vernakalant
infusion. However, 11 patients (31%) experienced a drop
in blood pressure below 60mmHg, which required the
administration of additional vasopressors in 4 of them. The
changes in blood pressure were only transient and no patient
was harmed thereby. However, these results support close
hemodynamic monitoring during the vernakalant infusion
and the following 2 hours with the possibility to react in cases
of hypotension.The fact that blood pressure was significantly
higher in nonresponders 30 and 120minutes after the vernak-
alant infusion suggests that hypotension was not only a result
of the study drug infusion but also a consequence of changes
in heart rhythm and rate.
Kowey reported any episode of hypotension or brady-
cardia in 9.3% and 13.1% of vernakalant-treated cardiosurgi-
cal patients, respectively [17]. However, severe hypotension
(systolic blood pressure <90mmHg) and severe bradycardia
(heart rate <40/min) occurred only in 5.6% and 3.7%, respec-
tively.TheARVO study revealed severe adverse effects (symp-
tomatic bradycardia or bradycardia <40/min, symptomatic
hypotension of systolic blood pressure <85mmHg, among
others) during the 2-hour observation period in 5/116 (2.6%)
of the patients [19]. The risk of hypotension might have
been a bit higher in our ICU patients because of a lower
blood pressure at baseline. Low blood pressure was easily
manageable in the ICU setting but could potentially have led
to more serious consequences without appropriate monitor-
ing. Based on our data and the findings from the literature,
we recommend to monitor blood pressure and heart rate
during and for 120 minutes after the vernakalant infusion.
No ventricular tachycardia or torsades de pointes occurred
in the vernakalant-treated patients. Our results correspond
to previous reports in which vernakalant did not prolong
QTc or QRS intervals, and no proarrhythmic side effects
were observed [14]. In the ACT trials I–IV, most common
side effects were bradycardia and hypotension, but no deaths
or proarrhythmic effects including torsades de pointes were
reported in these studies [15–18].
4.4. Limitations of the Study. More detailed pieces of hemo-
dynamic information including stroke volume or cardiac
filling pressures were not available in our patients, as we
only included hemodynamically stable patients in whom
pulmonary artery catheters had been removed by the time of
AF onset.
Vernakalant was also administered to intubated patients,
in whom electrical cardioversion would have been a rea-
sonable treatment option [23]. But as previously described,
success rates after electrical conversion [21] might not be
better than the ones published in our study. In nonintu-
bated patients, drug treatment is favorable over electrical
conversion, because it avoids the need for sedation with the
subsequent risks of blood pressure compromise, respiratory
arrest, and aspiration/asphyxia.
5. Conclusions
To our knowledge, this is the first report on the usefulness
of vernakalant in ICU patients. We demonstrated that only
a minority of postoperative ICU patients with new onset
AF qualified for vernakalant when inclusion and exclusion
criteria provided by the manufacturer were strictly applied.
The conversion rate of >50% was comparable to published
data in noncritically ill patients. Vernakalant administra-
tion was generally safe, but heart rate and blood pressure
monitoring during and 2 hours after drug administration
is still recommended because of the occasional episodes of
hypotension and bradycardia. Due to its favorable safety pro-
file, vernakalant represents an interesting treatment option
for new onset AF in critically ill patients. Future research
is needed to investigate if pre- and/or posttreatment with
other antiarrhythmic drugs (e.g., with esmolol) can improve
the conversion rate of vernakalant and reduce the risk of AF
recurrence in responders.
Disclosure
Sacha P. Salzberg received honoraria from MSD/Essex
Chemie AG, which distributed vernakalant in Switzerland,
when the study was initiated. Alain Rudiger received hono-
raria fromAOP Pharma, which is distributing vernakalant in
Switzerland since 2013.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] M. Arrigo, D. Bettex, and A. Rudiger, “Managment of atrial
fibrillation in critically ill patients,” Critical Care Research and
Practice, vol. 2014, Article ID 840615, 10 pages, 2014.
[2] D. Annane, V. Se´bille, D. Duboc et al., “Incidence and prognosis
of sustained arrhythmias in critically III patients,” American
Journal of Respiratory and Critical Care Medicine, vol. 178, no.
1, pp. 20–25, 2008.
[3] M. K. Chung, “Cardiac surgery: postoperative arrhythmias,”
Critical Care Medicine, vol. 28, no. 10, pp. N136–N144, 2000.
[4] T. C. Andrews, S. C. Reimold, J. A. Berlin, and E. M. Antman,
“Prevention of supraventricular arrhythmias after coronary
artery bypass surgery. A meta-analysis of randomized control
trials,” Circulation, vol. 84, no. 5, pp. III236–III244, 1991.
[5] G. H. Almassi, T. Schowalter, A. C. Nicolosi et al., “Atrial fibril-
lation after cardiac surgery: a major morbid event?” Annals of
Surgery, vol. 226, no. 4, pp. 501–513, 1997.
[6] H. F. McAlister, R. A. Luke, R. M. Whitlock, and W. M. Smith,
“Intravenous amiodarone bolus versus oral quinidine for atrial
flutter and fibrillation after cardiac operations,” Journal of
Thoracic and Cardiovascular Surgery, vol. 99, no. 5, pp. 911–918,
1990.
[7] E. O. Bernard, E. R. Schmid, D. Schmidlin, C. Scharf, R.
Candinas, and R. Germann, “Ibutilide versus amiodarone in
atrial fibrillation: a double-blinded, randomized study,” Critical
Care Medicine, vol. 31, no. 4, pp. 1031–1034, 2003.
[8] P. R. Kowey, R. A. Marinchak, S. J. Rials, and R. A. Filart, “Acute
treatment of atrial fibrillation,” American Journal of Cardiology,
vol. 81, no. 5, pp. 16C–22C, 1998.
Critical Care Research and Practice 7
[9] G. E. Kochiadakis, N. E. Igoumenidis, M. E. Hamilos, M. E.
Marketou, G. I. Chlouverakis, and P. E. Vardas, “A compar-
ative study of the efficacy and safety of procainamide versus
propafenone versus amiodarone for the conversion of recent-
onset atrial fibrillation,”American Journal of Cardiology, vol. 99,
no. 12, pp. 1721–1725, 2007.
[10] D. Fedida, “Vernakalant (RSD1235): a novel, atrial-selective
antifibrillatory agent,” Expert Opinion on Investigational Drugs,
vol. 16, no. 4, pp. 519–532, 2007.
[11] D. Fedida, P. M. R. Orth, J. Y. C. Chen et al., “Themechanism of
atrial antiarrhythmic action of RSD1235,” Journal of Cardiovas-
cular Electrophysiology, vol. 16, no. 11, pp. 1227–1238, 2005.
[12] P. Dorian, A. Pinter, I. Mangat, V. Korley, S. S. Cvitkovic, and
G. N. Beatch, “The effect of vernakalant (RSD1235), an inves-
tigational antiarrhythmic agent, on atrial electrophysiology in
humans,” Journal of Cardiovascular Pharmacology, vol. 50, no.
1, pp. 35–40, 2007.
[13] P. Friederich and H. Pfizenmayer, “The novel Kv1.5 channel
blocker vernakalant for successful treatment of new-onset atrial
fibrillation in a critically ill abdominal surgical patient,” British
Journal of Anaesthesia, vol. 107, no. 4, pp. 644–645, 2011.
[14] D. Roy, B. H. Rowe, I. G. Stiell et al., “A randomized, controlled
trial of RSD1235, a novel anti-arrhythmic agent, in the treatment
of recent onset atrial fibrillation,” Journal of the American
College of Cardiology, vol. 44, no. 12, pp. 2355–2361, 2004.
[15] D. Roy, C. M. Pratt, C. Torp-Pedersen et al., “Vernakalant
hydrochloride for rapid conversion of atrial fibrillation: a phase
3, randomized, placebo-controlled trial,” Circulation, vol. 117,
no. 12, pp. 1518–1525, 2008.
[16] C. M. Pratt, D. Roy, C. Torp-Pedersen et al., “Usefulness of
vernakalant hydrochloride injection for rapid conversion of
atrial fibrillation,” American Journal of Cardiology, vol. 106, no.
9, pp. 1277–1283, 2010.
[17] P. R. Kowey, P. Dorian, L. B. Mitchell et al., “Vernakalant hydro-
chloride for the rapid conversion of atrial fibrillation after car-
diac surgery a randomized, double-blind, placebo-controlled
trial,” Circulation: Arrhythmia and Electrophysiology, vol. 2, no.
6, pp. 652–659, 2009.
[18] I. G. Stiell, J. S. Roos, K. M. Kavanagh, and G. Dickinson, “A
multicenter, open-label study of vernakalant for the conversion
of atrial fibrillation to sinus rhythm,” American Heart Journal,
vol. 159, no. 6, pp. 1095–1101, 2010.
[19] A. J. Camm, A. Capucci, S. H. Hohnloser et al., “A randomized
active-controlled study comparing the efficacy and safety of
vernakalant to amiodarone in recent-onset atrial fibrillation,”
Journal of the American College of Cardiology, vol. 57, no. 3, pp.
313–321, 2011.
[20] C. Torp-Pedersen, A. J. Camm, N. N. Butterfield, G. Dickinson,
and G. N. Beatch, “Vernakalant: conversion of atrial fibrillation
in patients with ischemic heart disease,” International Journal of
Cardiology, vol. 166, pp. 147–151, 2013.
[21] A. Mayr, N. Ritsch, H. Knotzer et al., “Effectiveness of direct-
current cardioversion for treatment of supraventricular tach-
yarrhythmias, in particular atrial fibrillation, in surgical inten-
sive care patients,” Critical Care Medicine, vol. 31, no. 2, pp. 401–
405, 2003.
[22] D. Conde, N. Lalor, L. Rodriguez, P. Elissamburu, and T.
Marcelo, “Vernakalant versus electrical cardioversion in recent-
onset atrial fibrillation,” International Journal of Cardiology, vol.
168, pp. 4431–4432, 2013.
[23] A. J. Camm, P. Kirchhof, G. Y. Lip et al., “Guidelines for the
management of atrial fibrillation: the task force for the manage-
ment of atrial fibrillation of the European Society of Cardiology
(ESC),” European Heart Journal, vol. 31, no. 19, pp. 2369–2429,
2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
